Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBX-12 in Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
NCT06730100Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of alphalex exatecan in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Sep 2025; status: active, not recruiting.
02
Drugs
alphalex exatecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06730100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730100.